Aragon Pharmaceuticals Scores $42M

San Diego-based Aragon Pharmaceuticals reports this morning that the firm has raised $42M in a Series C, funding round. The firm, which is developing treatments targeting hormone-driven cancers, said the round was led by Topspin Fund, the investment group of James Simons, Leo A. Guthart and Steve Winick, and also included Aisling Capital, OrbiMed Advisors and The Column Group. The firm said the new round brings its total raised to $72M. Topspin Capital's Leo A. Guthart, and former Calistoga Pharmaceuticals' President and CEO Carol G. Gallagher join the firm's board along with the funding. The company is initially focusing on prostate cancer treatment. More information »